You searched for "consent"
Junior doctors’ strike: is there light at the end of the tunnel?
Most urology departments will be affected one way or another by the ongoing industrial action by our junior colleagues. This article gives an interview between the BMJ team and Jeremy Hunt, UK Secretary of State for Health. We may or...Purple urine bag syndrome
Purple urine bag syndrome (PUBS) is an uncommon phenomenon where the tubing and urinary catheter bag is noticed to undergo purple discolouration. This has been linked with urinary tract infections (UTI), chronic debilitated states and prolonged catheterisation. PUBS was noticed...Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...Focal therapies in prostate cancer
The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...Demanding cases or nightmares in endourology? Sep/Oct 2016
In this issue the authors will present once in a career cases that can truly haunt a urologist. “Mistakes are like bad loves, the more you learn from them, the more you wish they’d never happened. “ Gregory David Roberts*...
Oncological benefits of extended pelvic lymph node dissection
Touijer and colleagues present extended follow-up results from a large randomised trial comparing limited pelvic lymph node dissection (l-PLND) and extended PLND (e-PLND) in prostate cancer patients undergoing radical prostatectomy. The study aimed to assess whether e-PLND, which includes external...
Anti-VEGF and PD-1 combinations in renal cell carcinoma
Over the past decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been central to treating renal cell carcinoma (RCC), with oncologists refining dosing strategies to balance treatment efficacy with quality of life (QoL). Recently, the introduction of...
